Unknown

Dataset Information

0

Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients.


ABSTRACT: BACKGROUND:The surrogate immunohistochemical marker, p16INK4a, is used in clinical practice to determine the high-risk human papillomavirus (HPV) status of oropharyngeal squamous cell carcinomas (OPSCC). With a specificity of 83%, this will misclassify some patients compared with direct HPV testing. Patients who are p16INK4a-positive but HPV DNA-negative, or RNA-negative, may be unsuitable for treatment de-escalation aimed at reducing treatment-related side effects. We aimed to identify cost-effective serum markers to improve decision making for patients at risk of misclassification by p16INK4a alone. METHODS:Serum proteins from pre-treatment samples of 36 patients with OPSCC were identified and quantified using label-free mass spectrometry-based proteomics. HPV-status was determined using p16INK4a/HPV DNA and E6/E7 mRNA. Serum protein expressions were compared between groups of patients according to HPV status, using the unpaired t-test with a Benjamini-Hochberg correction. ROC curves (AUC) were calculated with SPSS (v25). RESULTS:Of 174 serum proteins identified, complement component C7 (C7), apolipoprotein F (ApoF) and galectin-3-Binding Protein (LGALS3BP) significantly differed between HPV-positive and -negative tumors (AUC ranging from 0.84-0.87). ApoF levels were more than twice as high in the E6/E7 mRNA HPV-positive group than HPV-negative. CONCLUSIONS:Serum C7, ApoF and LGALS3BP levels discriminate between HPV-positive and HPV-negative OPSCC. Further studies are needed to validate these host immunity-related proteins as markers for HPV-associated OPSCC.

SUBMITTER: Dickinson A 

PROVIDER: S-EPMC7295232 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparing serum protein levels can aid in differentiating HPV-negative and -positive oropharyngeal squamous cell carcinoma patients.

Dickinson Amy A   Saraswat Mayank M   Syrjänen Stina S   Tohmola Tiialotta T   Silén Robert R   Randén-Brady Reija R   Carpén Timo T   Hagström Jaana J   Haglund Caj C   Mattila Petri P   Mäkitie Antti A   Joenväärä Sakari S   Silén Suvi S  

PloS one 20200615 6


<h4>Background</h4>The surrogate immunohistochemical marker, p16INK4a, is used in clinical practice to determine the high-risk human papillomavirus (HPV) status of oropharyngeal squamous cell carcinomas (OPSCC). With a specificity of 83%, this will misclassify some patients compared with direct HPV testing. Patients who are p16INK4a-positive but HPV DNA-negative, or RNA-negative, may be unsuitable for treatment de-escalation aimed at reducing treatment-related side effects. We aimed to identify  ...[more]

Similar Datasets

| S-EPMC1847595 | biostudies-literature
| S-EPMC9221036 | biostudies-literature
| S-EPMC7352546 | biostudies-literature
| S-EPMC9947859 | biostudies-literature
| S-EPMC3530794 | biostudies-literature
2014-04-24 | MSV000078610 | MassIVE
| S-EPMC9863220 | biostudies-literature
2014-03-05 | GSE55542 | GEO
2014-03-05 | E-GEOD-55542 | biostudies-arrayexpress
| S-EPMC8757728 | biostudies-literature